Low nuclear expression of DARPP-32 remained significantly associated with adverse survival (hazard ratio (HR): 0.766; 95% confidence interval (CI): 0.613–0.957; P = 0.019) when potentially confounding factors were included in multivariate assessment (including tumour size, stage, grade, NPI status, vascular invasion status, ER, PgR and HER2 receptor status (all with log-rank statistics of P < 0.001) (Table 2). Here, PPP1R1B is linked to neoplasm.